Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

7.8K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.8K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

642
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
642

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Is the era of personalized dosimetry in hepatic radioembolization coming to an end?

Revista espanola de medicina nuclear e imagen molecular·2026
Same author

Clinicopathologic and metabolic variables from <sup>18</sup>F-FDG PET/CT in the prediction of recurrence pattern in stage I-III non-small cell lung cancer after curative surgery.

Annals of nuclear medicine·2025
Same author

Assessment of pulmonary nodules using [<sup>18</sup>F]-FDG PET/CT in deep inspiration breath-hold.

Revista espanola de medicina nuclear e imagen molecular·2024
Same author

Use of propranolol in [<sup>18</sup>F] FDG-PET/CT for differential diagnosis of brown fat in patient with a history of adenocarcinoma of the uterine cervix.

Revista espanola de medicina nuclear e imagen molecular·2024
Same author

<sup>18</sup>F-DCFPyL PET/CT guidelines.

Revista espanola de medicina nuclear e imagen molecular·2023
Same author

Contributions of nuclear medicine to malignant musculoskeletal tumor disease in children.

Revista espanola de medicina nuclear e imagen molecular·2022

Related Experiment Video

Updated: Feb 22, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.0K

68Ga-PSMA PET/CT in prostate cancer.

J R García Garzón1, M de Arcocha Torres2, R Delgado-Bolton3

  • 1Unitat PET/TC CETIR-ERESA, Esplugues de Llobregat, Barcelona, España.

Revista Espanola De Medicina Nuclear E Imagen Molecular
|September 25, 2017
PubMed
Summary

Gallium-68 Prostate-Specific Membrane Antigen (68Ga-PSMA) Positron Emission Tomography/Computed Tomography (PET/CT) aids in imaging prostate cancer. This technique visualizes increased PSMA expression, crucial for diagnosing and assessing the disease.

Keywords:
Cáncer de próstataPET/CTPET/TCPSAPSMAPrognosisPronósticoProstate cancerRecidivaRelapse

More Related Videos

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

984
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K

Related Experiment Videos

Last Updated: Feb 22, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.0K
Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

984
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

2.0K

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiochemistry

Background:

  • Prostate-specific membrane antigen (PSMA) is a transmembrane protein highly expressed in prostate tissues.
  • Elevated PSMA expression is observed in various malignancies, with prostate cancer exhibiting particularly high concentrations.
  • PSMA expression levels correlate with tumor dedifferentiation, metastasis, and hormone-refractory status, indicating prognostic value.

Purpose of the Study:

  • To evaluate the utility of 68Ga-PSMA Positron Emission Tomography/Computed Tomography (PET/CT) as a non-invasive diagnostic imaging technique for prostate cancer.
  • To assess the correlation between PSMA expression and disease characteristics in prostate cancer.

Main Methods:

  • Utilized 68Ga-PSMA PET/CT, a non-invasive diagnostic modality.
  • Employed Positron Emission Tomography (PET) to measure the three-dimensional distribution of 68Ga-PSMA.
  • Generated semi-quantitative images for assessing PSMA expression.

Main Results:

  • 68Ga-PSMA PET/CT effectively images prostate cancer with increased PSMA expression.
  • Almost all prostate adenocarcinomas demonstrate PSMA expression in primary and metastatic lesions.
  • Immunohistochemistry confirms increased PSMA expression in de-differentiated, metastatic, or hormone-refractory tumors.

Conclusions:

  • 68Ga-PSMA PET/CT is a valuable non-invasive tool for visualizing PSMA expression in prostate cancer.
  • PSMA expression levels assessed by PET/CT provide insights into tumor characteristics and prognosis.
  • The technique allows for the non-invasive assessment of PSMA expression, aiding in prostate cancer management.